Search Tag: Tirzepatide

2025 11 Sep

Fewer than half of people in England can currently access tirzepatide (Mounjaro) through their GP, despite the NHS weight-loss jab being officially rolled out more than two months ago, a BMJ investigation has found.   Because of the drug’s high cost and the scale of potential demand, around 3.4 million people could benefit, NHS England and the...Read more

2025 13 May

A new head-to-head clinical trial comparing tirzepatide and semaglutide for weight loss in people with obesity but without diabetes demonstrates that tirzepatide led to significantly greater weight reduction. Over a 72-week period, participants receiving tirzepatide achieved an average weight loss of 20.2%, compared to 13.7% with semaglutide—a difference...Read more

2024 29 Oct

According to a study led by the Yale School of Public Health and the University of Florida, expanding access to new, highly effective weight-loss medications could save over 40,000 lives annually in the U.S. The research highlights the urgency of removing barriers that prevent people from accessing effective obesity treatments, a crucial step toward...Read more

2024 26 Mar

A recent investigation featured in the Diabetes Technology & Therapeutics journal explored the use of tirzepatide among overweight/obese adults with type 1 diabetes.   Tirzepatide, approved for managing type 2 diabetes, has garnered attention for its ability to enhance glucose regulation, foster weight reduction, and promote cardiovascular health....Read more